{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-22-000040","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2022-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.422304+00:00","generated_at":"2026-06-24T21:47:05.138278+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Centessa board adds ex-BMS regulatory exec; director Kantoff resigns","bullets":["Aaron Kantoff resigned from Centessa board effective July 1, 2022; no disagreement cited, will remain as advisor.","Mathias Hukkelhoven, former SVP Global Regulatory at BMS, appointed to board and Nominating & Governance Committee.","Hukkelhoven receives initial option for 96,000 ordinary shares vesting over 3 years, plus annual grants of 48,000 shares.","Dr. Hukkelhoven also serves on Compugen (CGEN) board and as advisor to McKinsey and LianBio."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-22-000040","json":"https://secwatch.observer/filing/0001847903-22-000040.json","markdown":"https://secwatch.observer/filing/0001847903-22-000040.md","text":"https://secwatch.observer/filing/0001847903-22-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/cnta-20220701.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T21:47:05.138278+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fa4de046c","claim":"Mathias Hukkelhoven was appointed as director at Centessa Pharmaceuticals plc.","evidence_excerpt":"On July 1, 2022, upon the recommendation of its Nominating and Corporate Governance Committee, the Board appointed Mathias Hukkelhoven, Ph.D. to join the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"d35007143a","claim":"Aaron Kantoff resigned as director at Centessa Pharmaceuticals plc.","evidence_excerpt":"On July 1, 2022, Aaron Kantoff, a member of the board of directors (the “Board”) of Centessa Pharmaceuticals plc (the “Company”) , notified the Company of his resignation from the Board, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790322000040/0001847903-22-000040-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}